The report on the global Companion Diagnostic Cancer Biomarkers market is a complete overview of the market, covering various aspects product definition, segmentation based on various parameters, and the prevailing vendor landscape. It compiles in-depth information and research methodologies. It is also combined with relevant charts and tables to enable readers to get a better perspective of this global market. A cancer biomarker refers to a substance or procedure that gives indication for the presence of cancer in the body. These biomarkers are endogenous proteins or metabolites whose amounts or modifications reveal tumor state, progression characteristics and response to therapies. In recent years, research on cancer biomarkers has increased immensely. This research is providing great opportunities for improving the management of cancer patients by enhancing the efficiency of detection and effectiveness of treatment. Recent technological advancements have enabled the examination of many potential biomarkers and developed interest in new biomarkers.
Brows Complete Report now at https://goo.gl/xCWd4d
Based on its type, the Global Companion Diagnostic Cancer Biomarkers Market is segmented into: Protein Biomarkers, Genetic Biomarkers, and Other Cancer Biomarkers
Protein Biomarkers product type accounted for major share of global companion diagnostic cancer biomarkers market in 2015 and other types are also predicted to follow the lead and further fuel the growth of this market.
Get 20% Discount on this report now at https://goo.gl/HPPELq
By its application type, the Global Companion Diagnostic Cancer Biomarkers Market is segmented into: Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Gastric and Others (Cervical, Kidney, Leukemia, etc.)
Cancer remains the disease that is feared by most of the people, which is why there is a need to constantly research and improve health. New technologies are supporting crucial surveillance and research for analysis so as to gain insight into factors that influence health and cancer or disease. Moreover, with further development and support, these technologies have tremendous potential to advance the cancer research. With the rising demand for unleashing new possibilities for improving healthcare, technological advancements are, creating a rapid growth in this market. Breast Cancer application stood as the largest and fastest growing application segment for Companion Diagnostic Cancer Biomarkers market in 2015 and is expected grow in the near future. Global Companion Diagnostic Cancer Biomarkers market is expected to develop at a CAGR of 15.0% during the forecast period.
Enquiry Before Buying: https://goo.gl/WcOryG
A companion diagnostic is a medical device, often an in-vitro device providing information that is essential for the safe and effective use of a corresponding drug or biological product. Although companion diagnostics promises to bring new efficiencies to the healthcare system, there is an additional layer of complexity. The current reimbursement system was designed to support relatively simple diagnostic tests that formed the basis of the traditional diagnostics industry. This system is not designed to support companion diagnostic cancer biomarkers and research, and hence hampers the progress of the market.
On the basis of regions, the Global Companion Diagnostic Cancer Biomarkers Market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. North America accounted for major share of global Companion Diagnostic Cancer Biomarkers market in 2015 and is expected to increase in the near future. Other regions are also predicted to follow the lead and further fuel the growth of this market.
The major key players of this market are Abbott Diagnostics, Agilent Technologies, Eli Lilly & Co., EUSA Pharma, CytoCore, Inc., GE Healthcare, Bruker Daltonics, Inc., Biomarker Technologies, LLC, BioCurex, Inc., Asuragen, Inc., DiagnoCure, Inc., and Beckman Coulter, Inc.